Nevia bio News
5 articles
growth-positive
Nevia Bio Completes a $3M Seed Round to Build a Machine Learning-Enabled Platform for Early Detection of Women-Related Diseases
Nevia Bio, a company developing a machine learning empowered platform for early detection of womens health indications, has announced the completion of a $3.1M Seed Round. The funding will be used to support the companys clinical trials in ovarian cancer and to expand its pipeline to additional indications in womens health. Nevia Bios platform decodes information from womens vaginal secretions using machine learning tools to identify specific biomarkers for early detection of diseases. The company has conducted clinical trials and established a biobank of more than 900 samples. Nevia Bio is backed by investors including MindUP Digital Health Incubator, Pitango HealthTech, Alive Israel HealthTech Fund, and the Technion.
Investment
growth-positive
Nevia Bio is using AI to early detect "silent killer" ovarian cancer | CTech
Nevia Bio, formerly known as Gina Life, is a company that aims to democratize preventative medicine and make ovarian cancer screenings accessible to all. Co-founder and CEO Dr. Inbal Zafir-Lavie shared her personal motivation for starting the company, which was the loss of her sister to colorectal cancer. Nevia Bio uses a machine learning model to analyze vaginal secretions for early detection of ovarian cancer, as 75% of women are diagnosed at later stages with poor survival rates. The companys goal is to develop a home-use test that can be ordered online, making it simple and affordable for women to access. Nevia Bio is currently initiating a U.S.-based clinical trial and pursuing FDA approval.
Customers
growth-positive
The FemTech revolution: 7 Israeli companies making headlines in women's health | CTech
The global FemTech market size is expected to grow from $28B in 2021 to $33B in 2022. In Israel, investments in MedTech reached $2.4B in 2021, with FemTech accounting for 6% of the total. The article highlights 7 Israeli FemTech companies making headlines: AiVF, Aquafit, Ginalife, Illumigyn, Ocon Healthcare, Pulsenmore, and Tulipon. These companies are involved in various areas of female health, such as AI-based IVF treatments, intimate gel stick products, early disease detection using AI, gynecology endoscope technology, intrauterine drug delivery, and pregnancy scanning. The companies have received funding from private equity, scientific grants, the Israel Innovation Authority, and various investors. Some companies have also signed distribution agreements and partnerships with global players in the industry. The article emphasizes the growth potential of the FemTech sector and the need for greater recognition.
InvestmentExpand
growth-positive
The femtech duo analyzing discharge to detect female-related diseases
Gina Life, a femtech company co-founded by Dr. Shlomit Yehudai-Reshef and Dr. Inbal Zafir-Lavie, is developing a home-testing kit to detect diseases from endometriosis to cervical cancer using vaginal discharge. The kit, which is expected to be available by 2025, uses a smart pad to provide early diagnosis for a variety of medical conditions. The company has raised over a million dollars in two successful fundraising rounds and recently won the Boston MassChallenge startup accelerator competition. Gina Life is also developing a smartphone app that can analyze the strips on the pad using an artificial intelligence-based algorithm.
InvestmentExpand
growth-positive
Shaping the future of ovarian cancer diagnosis with femtech -
Israeli femtech start-up GinaLife is developing a platform that uses artificial intelligence and data science to detect early signs of problems in womens health. The companys first product is focused on the early detection of ovarian cancer. The test in development analyses vaginal fluids for specific cancer biomarkers. The company has received funding from Israel’s government and is preparing to raise funds for clinical trials in the US and UK. GinaLife is also running a clinical trial for endometriosis and expects to have the first generation of product for ovarian cancer ready in two years.
InvestmentExpand
